Dunia Crypto: AIMEDIS

What is AIMEDIS?

AIMEDIS is a company on the frontier of e-health research and development, already operating

in more than 20 hospitals in 3 countries with more than 10,000 patients.

AIMEDIS is currently raising funds to develop version 2 of the AIMEDIS platform, using a dual

blockchain system for data immutability and ownership, even selling it! Our goal is to provide

patients ownership of their data while giving viewing capabilities for this data for any doctor they

choose. The future of healthcare is digital, and AIMEDIS is positioning itself as a trailblazer,

allowing AI, wearables and social media to work together for better health outcomes for all of its

patients.

THE BUSINESS MODEL

Aimedis is designed to support the work of professionals as well as the treatment of patients.

Primarily, we target professionals in the health sector who are seeking a medical platform to interact with every stakeholder in the medical field considering the needs of data security and medical alignment.

The use of Aimedis allows a seamless connection to a variety of hospital information systems in use and fits regulations like HIPAA, IHE, HL7.

This offers a considerable potential to make workflows more efficient and barriers to entering the market low.

Moreover, hospitals and doctors can develop new revenue streams by using the platform, from offering video chat consultations to using the electronic prescription tool.

This device offers blockchain secured signings for remote prescriptions, which can then be directly issued to pharmacies all around the world.

Hospitals can also evaluate the progress and the success of patients; Aimedis will be equally consumer driven and therefore allow a continuous connection between the different parties.

Since medical markets do not work like other consumer or financial markets, it is not enough to have a good product that fills one need.

A new medical product will not just be used because it makes sense or even helps people getting better treatments.

It must also offer as many solutions in one program as possible to improve compliance and usability.

By replacing multiple programs (e.g., Mysugr, doctor on demand, HealthVault, etc.) with a one-stop solution like Aimedis, efficiency is vastly increased, and patient

outcomes are improved. A patient using the Aimedis system is also able to take pro-active control of their own care and play an active role in the management of

their own health and wellbeing.

Aimedis AI-protocols will extract anonymized information for medical and pharmaceutical research.

We have worked on developing and implementing digital solutions in the health market for several years, knowing that an approach considering only professional needs will fail - just as solutions for patients alone simply do not work.

We have been confronted with patients using multiple apps to store blood sugar, body weight, psychological profiles etc.

and doctors that refuse to spend time shifting from one app to the next to get an overview of a patient’s health.

It just makes sense to have all data on one platform and directly integrated into the health record accessible by both the patient and providers.

In the opinion of hundreds of doctors and thousands of patients we spoke to, this is a solution that is long overdue for adoption.

Due to the vast application spectrum of health care platform businesses we present some of our ongoing business cases which we already offer in cooperation with hospitals to help understand in detail our market approach.

In general partner hospitals, caregivers, insurance and other companies must hold AIM token valued at at least 20.000 USD in a wallet.

Based on that they can use the Aimedis services which will generate income by the participants.

1.Support of Patients after central nervous incidents like strokes with demand of long term treatment.

The SRH hospital group offer long term after care for patients in form of continuous

connection to the patient and the treating ambulatory institutions through video conferences, therapy videos which are taken in hospitals and afterwards as

documentation of progress and adequate exercise implementation. This networking effect has proven to increase quality of treatment.

2.Pre-and after care of cardiological patients from the Netherlands which undergo coronary angiography in Germany. Due to long waiting lists in the Netherlands and free capacities in Germany patients seek treatment beyond the border giving

hospitals in Germany additional revenue opportunities.

Contact, appointment and data transfer will be offered by hospitals using Aimedis.

Inside the platform Aimedis generates revenue, following a freemium model, while offering the possibility to buy additional medical services if required.

On patients’ side revenue is generated from paid online video consultations like psychotherapy, online prescriptions and 24 / 7 availability of consulting

doctors.

Resident doctors pay a fee for using video chat, the appointment system or the online prescription tool.

Cooperating hospitals have already started to use the platform to support their patients before and even after stationary treatment at home or while being

abroad. In that case revenues are generated by using paid services like the video chat platform, Aimedis appointment system, the online prescription tool and

data analysis on demand.

Healthcare providers will offer these additional services via the Aimedis platform, thus generating new revenue streams. Many countries currently change their regulations for telemedical care which results in cost coverage by health insurance companies.

Token

AIM Tokens are used in several ways.

First, AIM holders will participate in the health ecosystem and will benefit from the application and functionality.

Both the pharmaceutical industry and scientific research facilities can pay wages to patients for participating in trials and grant access to specific areas of their medical records, which are 100% voluntary.

In the next step AImedis will deliver AIM Social, a platform that pays patients to help and interact with other patients.

Costs and incentives are supported by patients by patients - all over the world.

AIMEDIS TOKEN (AIM) –

ICO STRUCTURE & DISTRIBUTION

Token type: ERC20 based token on Ethereum public blockchain

Maximum supply: 600.000.000 tokens

Available for purchase: 300.000.000 tokens

Price per token: 0,12 USD = 1 AIM

Emission rate: No new coins will be minted, created or mined after the ICO

Pre-ICO sale period: Q2 2018

25% bonus during pre-ICO period (20% discount)

Main ICO sale period: Q3 2018

Token can be used to access services inside the platform and services in the AIMedisafe backed online drugstore with discounts

Token will be used to reward participants in terms of sharing usefully voted content

in the AIMsocial medical social network

Researchers will incentivize patients for participating in trials via the token

Every professional institution (hospitals, scientific researchers) using the Aimedis portal will have to hold at least AIM tokens worth 20.000 USD at any time

Token issuance during presale and ICO via https://ico.aimedis.com, which will issue the tokens directly after the ICO

Team members, advisory board and supporters must hold their tokens for at least 12

months, after which only 25% of them can sold, after 24 months only the next 25% can be sold, after 36 months the next 25% and after 48 months the last 25%.

Contributors with equal or more than 25ETH in tokens must hold 90% of their tokens for at least 6 months, 10% of the tokens can be sold freely.

Those investors will get a tokens bonus if they hold their tokens for at least 12 months.

Legal surveillance by Wenger & Vieli attorneys at law, Zürich & Zug, Switzerland

AIMEDIS TOKENOMICS

1.The AIM token is not mined and the amount is fixed to 600.000.000 tokens

2. Token can be used to access services inside the platform with discounts

Hospitals and caregivers that hold the AIM token can access medical services like videochat, appointment modules, prescription modules and more services at a reduced price via the platform. Patients can access services that are not covered by their insurance company at a reduced price via the platform.

Insurance companies can get reduced prices for services inside the platform for their insured patients. All participants can get services via the AIMedisafe backed online pharmacy.

3. Token will be used to reward participants in terms of sharing usefully voted

content in the AIMsocial medical social network Patients can interact inside the social medical network freely. If a patient uploads useful content like videos / texts / images / content or creates and operates an Aimedis self-help group, other patients can upvote these actions which directly incentivises this patient by our token.

If applicable Aimedis will issue a second token (AIS) which will be fixed in a 1:10 ratio to the AIM token.

4.Researchers will incentivize patients for participating in trials via the token

5.20% of Aimedis revenue will directly flow into the AIMsocial fund, which will back

the AIMsocial platform and will always make sure the AIMsocial system has

enough tokens.

6.The token enables the user to contribute to content creators via upvote + direct

contribution